ENOV
NEUTRAL
$24.1
Live
Enovis Corporation · NYSE
Target $44.73
(+85.6%)
$21.0
52W Range
$37.85
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 27, 2026
Market cap
$1.39B
P/E
N/A
ROE
-58.3%
Profit margin
-52.7%
Debt/Equity
0.92
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
Enovis Corporation presents a classic 'deep value' paradox, characterized by a stable Piotroski F-Score of 4/9 but severe bottom-line profitability issues. While the company trades at a significant discount to book value (P/B 0.93) and a very low forward P/E (6.03), its net profit margin is deeply negative at -52.69%. The stock is supported by a strong track record of earnings beats and bullish analyst targets, but this is countered by a disastrous long-term price trend and high execution risk associated with its acquisition-led growth strategy.
Key Strengths
Extreme valuation discount with Price/Book at 0.93 and Price/Sales at 0.62
Strong gross margins of 60.88% indicating a healthy core product value
Exceptional earnings track record with consistent beats over 25 quarters
Solid short-term liquidity with a Current Ratio of 2.02
Strong analyst conviction with a 'Strong Buy' consensus and target price of $44.73
Key Risks
Severe net losses resulting in a profit margin of -52.69% and negative ROE
High integration risk due to an aggressive acquisition-led growth strategy
Strong bearish technical momentum with a 5-year price decline of 68.9%
Stagnant organic revenue growth at only 2.60% YoY
Negative insider sentiment with recent selling activity
AI Fair Value Estimate
Based on comprehensive analysis
$35.0
+45.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
42
Moderate
92
55
20
45
0
AI Verdict
Speculative Value Play
Key drivers: Extreme valuation discount, Poor net profitability, Consistent earnings surprises, Bearish price action
Confidence
85%
Value
92/100
Ref P/E 6.03, P/B 0.93, P/S 0.62
Positives
- P/B < 1.0
- Forward P/E of 6.03 is exceptionally low for Healthcare
Watchpoints
- Low PEG ratio suggests growth is not justifying the current valuation
Future
55/100
Ref Growth rates and 10-K risk factors
Positives
- Consistent EPS beats
- Aggressive expansion via acquisitions
Watchpoints
- Slow YoY revenue growth (2.6%)
- High risk of acquisition failure
Past
20/100
Ref Historical price trends
Positives
- Consistent quarterly earnings progression
Watchpoints
- 5Y Change -68.9%
- 1Y Change -31.4%
Health
45/100
Ref Piotroski F-Score and ROE
Positives
- Current Ratio 2.02
- Manageable Debt/Equity 0.92
Watchpoints
- Piotroski F-Score 4/9 (Stable but not strong)
- ROE -58.27%
Dividend
0/100
Ref Yield 0%
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$24.1
Analyst Target
$44.73
Upside/Downside
+85.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ENOV and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ENOV
Enovis Corporation
Primary
|
-68.9% | -58.1% | -31.4% | -26.7% | +6.5% | -8.4% |
|
NVCR
NovoCure Limited
Peer
|
-93.7% | -81.1% | -26.1% | -14.2% | -1.7% | +12.8% |
|
WVE
Wave Life Sciences Ltd.
Peer
|
+16.6% | +81.8% | +7.7% | +3.7% | -37.1% | -0.1% |
|
PGEN
Precigen, Inc.
Peer
|
-46.5% | +240.5% | +188.3% | +13.2% | +11.6% | -7.5% |
|
IMTX
Immatics N.V.
Peer
|
-10.0% | +69.3% | +162.7% | +0.7% | +4.0% | +0.8% |
ENO
Enovis Corporation
Primary
5Y
-68.9%
3Y
-58.1%
1Y
-31.4%
6M
-26.7%
1M
+6.5%
1W
-8.4%
NVC
NovoCure Limited
Peer
5Y
-93.7%
3Y
-81.1%
1Y
-26.1%
6M
-14.2%
1M
-1.7%
1W
+12.8%
WVE
Wave Life Sciences Ltd.
Peer
5Y
+16.6%
3Y
+81.8%
1Y
+7.7%
6M
+3.7%
1M
-37.1%
1W
-0.1%
PGE
Precigen, Inc.
Peer
5Y
-46.5%
3Y
+240.5%
1Y
+188.3%
6M
+13.2%
1M
+11.6%
1W
-7.5%
IMT
Immatics N.V.
Peer
5Y
-10.0%
3Y
+69.3%
1Y
+162.7%
6M
+0.7%
1M
+4.0%
1W
+0.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
6.03
PEG Ratio
3.45
P/B Ratio
0.93
P/S Ratio
0.62
EV/Revenue
1.21
EV/EBITDA
7.38
Market Cap
$1.39B
Profitability
Profit margins and return metrics
Profit Margin
-52.69%
Operating Margin
6.09%
Gross Margin
60.88%
ROE
-58.27%
ROA
1.09%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+2.64%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.92
Moderate
Current Ratio
2.02
Strong
Quick Ratio
0.8
Poor
Cash/Share
$0.64
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.6B
Gross Margin
60.7%
Op. Margin
8.4%
Net Margin
-90.4%
Total Assets
$3.8B
Liabilities
$2.3B
Equity
$1.5B
Debt/Equity
1.57x
Operating CF
$0.1B
CapEx
$-0.1B
Free Cash Flow
$0.0B
FCF Yield
36%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$0.95
+13.1% surprise
2025-11-06
$0.75
+15.6% surprise
2025-08-07
$0.79
+9.9% surprise
Healthcare Sector Comparison
Comparing ENOV against 551 companies in the Healthcare sector
(31 bullish, 164 neutral, 356 bearish)
Return on Equity (ROE)
-58.27%
This Stock
vs
-89.58%
Sector Avg
-35.0%
(Below Avg)
Profit Margin
-52.69%
This Stock
vs
-16.45%
Sector Avg
+220.3%
(Superior)
Debt to Equity
0.92
This Stock
vs
2.7
Sector Avg
-65.8%
(Less Debt)
Revenue Growth
2.6%
This Stock
vs
125.97%
Sector Avg
-97.9%
(Slower)
Current Ratio
2.02
This Stock
vs
4.51
Sector Avg
-55.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ENOV
Enovis Corporation
|
NEUTRAL | $1.39B | - | -58.3% | -52.7% | $24.1 | |
|
NVCR
NovoCure Limited
|
BEARISH | $1.38B | - | -38.9% | -20.8% | $12.17 | Compare |
|
WVE
Wave Life Sciences Ltd.
|
BEARISH | $1.38B | - | -55.0% | -% | $7.31 | Compare |
|
PGEN
Precigen, Inc.
|
BEARISH | $1.4B | - | -572.0% | -% | $3.95 | Compare |
|
IMTX
Immatics N.V.
|
BEARISH | $1.4B | - | -37.1% | -% | $10.43 | Compare |
ENOV
Enovis Corporation
NEUTRAL
Mkt Cap
$1.4B
P/E
-
ROE
-58.3%
Price
$24.1
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | ORTIZ CHRISTINE | Director | Stock Award | 770 | - |
| 2026-03-13 | ENGERT OLIVER | Officer | Purchase | 1,000 | $23,740 |
| 2026-03-10 | ENGERT OLIVER | Officer | Purchase | 1,000 | $23,930 |
| 2026-03-09 | MCDONALD DAMIEN | Chief Executive Officer | Stock Award | 143,923 | - |
| 2026-03-09 | TANDY BRADLEY J | Officer | Stock Award | 25,586 | - |
| 2026-03-09 | LANG PATRICIA A | Officer | Stock Award | 25,586 | - |
| 2026-03-09 | KLECKNER JOHN | Officer | Stock Award | 14,925 | - |
| 2026-03-09 | BERRY PHILLIP BENJAMIN BEN | Chief Financial Officer | Stock Award | 47,974 | - |
| 2026-03-09 | ROSS TERRY D | Officer | Stock Award | 36,247 | - |
| 2026-03-09 | VOGT LOUIS | Officer | Stock Award | 36,247 | - |
| 2026-03-09 | ENGERT OLIVER | Officer | Purchase | 1,750 | $41,700 |
| 2026-03-04 | ENGERT OLIVER | Officer | Purchase | 1,250 | $31,045 |
| 2026-02-27 | ENGERT OLIVER | Officer | Purchase | 1,000 | $25,500 |
| 2026-01-05 | ENGERT OLIVER | Officer | Stock Award | 42,640 | - |
| 2025-12-31 | LALOR ANGELA S | Director | Stock Award | 845 | - |
ORTIZ CHRISTINE
Director
2026-03-31
770 shares
ENGERT OLIVER
Officer
2026-03-13
1,000 shares
·
$23,740
ENGERT OLIVER
Officer
2026-03-10
1,000 shares
·
$23,930
MCDONALD DAMIEN
Chief Executive Officer
2026-03-09
143,923 shares
TANDY BRADLEY J
Officer
2026-03-09
25,586 shares
LANG PATRICIA A
Officer
2026-03-09
25,586 shares
KLECKNER JOHN
Officer
2026-03-09
14,925 shares
BERRY PHILLIP BENJAMIN BEN
Chief Financial Officer
2026-03-09
47,974 shares
ROSS TERRY D
Officer
2026-03-09
36,247 shares
VOGT LOUIS
Officer
2026-03-09
36,247 shares
ENGERT OLIVER
Officer
2026-03-09
1,750 shares
·
$41,700
ENGERT OLIVER
Officer
2026-03-04
1,250 shares
·
$31,045
ENGERT OLIVER
Officer
2026-02-27
1,000 shares
·
$25,500
ENGERT OLIVER
Officer
2026-01-05
42,640 shares
LALOR ANGELA S
Director
2025-12-31
845 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
Enovis Corporation is a medical technology company that expanded its reconstructive and prevention segments through seven acquisitions during 2025. Investment in the company carries a high degree of risk, specifically related to its acquisition-led growth strategy, government regulations, and potential litigation.
8-K
8-K
10-Q
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
11 analysts
Evercore ISI Group
2026-04-06
Outperform
Outperform
BTIG
2026-02-26
Buy
Buy
Needham
2026-02-26
Buy
Buy
BTIG
2026-01-06
Buy
Canaccord Genuity
2025-12-17
Buy
Buy
Freedom Capital Markets
2025-12-17
Buy
Wells Fargo
2025-11-07
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ENOV from our newsroom.
Newest → oldest
No matching news yet.